Black Diamond Therapeutics 3Q 2026: Revenue $0, EPS ($0.17) — 10-Q Summary
Black Diamond Therapeutics reported no revenue and a widened net loss of $10.01M for 3Q 2026, with EPS at ($0.17). R&D expenses decreased for Silevertinib in NSCLC but increased for GBM. The company plans a Phase 3 trial for EGFR-NCM NSCLC, targeting initiation in 2Q 2027, and completed a safety lead-in for a GBM trial.
How this was made
The 30-second read
Why it matters
The earnings miss and zero revenue likely trigger short‑term downside, but the announced Phase 3 trial could be a catalyst later in 2027.
Market read
Primary earnings disclosure for a micro‑cap biotech; immediate trading relevance for short‑term positions.
What to watch
Upcoming Phase 3 trial initiation in 2Q 2027 could unlock future value; current numbers do not reflect potential pipeline milestones.
Background
The article is an AI‑generated summary of Black Diamond Therapeutics' Form 10‑Q filing for Q3 2026, highlighting financial and trial updates.
Ticker impact
Black Diamond Therapeutics posted Q3 2026 results with $0 license revenue and a widened net loss of $10.01M, marking the first public disclosure of its quarterly earnings.
downward pressure as investors price in the lack of revenue and widening loss
Earnings surprise is negative; no revenue and higher G&A costs signal operational challenges.
Market effects
Biotech sector may see modest pressure as a peer reports a loss without revenue, highlighting funding risks for early‑stage oncology firms.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance; primarily affects micro‑cap biotech investors.
Counterpoint
If the Phase 2 trials progress successfully, the current loss may be viewed as a temporary funding burn, offering a potential buying opportunity at depressed prices.
Key entities
- CompanyBlack Diamond Therapeutics
Biotech firm developing Silevertinib for NSCLC and GBM.
